GlassScriptPhysician profile
Leonard Michael Glade
NPI 1669738993
$11,908.69
in general payments reported to CMS, 2019-2025
35 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $332 · 2021: $430 · 2022: $1,992 · 2023: $784 · 2024: $6,446 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,950 · Food and Beverage: $3,654 · Travel and Lodging: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,950.00 |
| Food and Beverage | $3,653.97 |
| Travel and Lodging | $372.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,165.13 | 2019-2025 | Diamondback Coronary, Supera, Esprit |
| Shockwave Medical, INC | $928.75 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $680.17 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $577.07 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $571.53 | 2021-2025 | |
| Recor Medical INC | $480.25 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Glaxosmithkline, LLC. | $410.68 | 2019-2025 | Trelegy Ellipta, Nucala |
| Surmodics, INC. | $333.26 | 2022 | |
| Medtronic, INC. | $305.70 | 2022-2024 | Venaseal, Closurefast, Linq II |
| Amgen INC. | $292.06 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $287.86 | 2021-2025 | Avvigo Guidance System, Ranger, Cds - Mct/Cem Monitoring |
| Alnylam Pharmaceuticals INC. | $218.05 | 2023-2024 | Onpattro |
| Bard Peripheral Vascular, INC. | $185.95 | 2019-2025 | Venovo |
| E.R. Squibb & Sons, L.L.C. | $183.13 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $172.57 | 2021-2024 | Xarelto |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $170.20 | 2023-2024 | Indigo System |
| Novo Nordisk INC | $144.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abiomed | $108.28 | 2020-2025 | |
| Esperion Therapeutics, INC. | $78.73 | 2024-2025 | Nexletol |
| Irhythm Technologies, INC. | $77.16 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Angiodynamics, INC. | $75.05 | 2023 | Auryon Laser System 100-120 Vac |
| Edwards Lifesciences Corporation | $71.35 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.87 | 2021-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.93 | 2024-2025 | Lifevest |
| Livanova USA, INC. | $42.99 | 2025 | Thn Sleep Therapy |
| Insmed, INC. | $42.46 | 2025 | Arikayce |
| Becton, Dickinson and Company | $28.47 | 2024 | Venclose Maven Catheter |
| Cardiva Medical, INC. | $26.56 | 2024 | Ensoetm |
| Pfizer INC. | $23.18 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.45 | 2025 | Gvoke Hypopen |
| Kestra Medical Technology Services, INC. | $21.32 | 2022 | |
| Philips North America LLC | $20.60 | 2022 | |
| Atricure, INC. | $18.81 | 2023 | |
| Inspire Medical Systems, INC. | $15.62 | 2023 | Inspire |
| Tactile Systems Technology INC | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Glade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.